The Company is engaged in discovering, developing and providing therapies that improve the lives of patients with hematologic disorders and cancer. The Company’s lead product, TAVALISSE tablets, the spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia . High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.
Bloomberg Markets European Close Bloomberg Markets European Close. Live from New York and London, analyzing the major market moving stories across the day in Europe, hear from the biggest newsmakers and showcase the unrivaled expertise of Bloomberg News. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index quotes are real-time. Provide specific products and services to you, such as portfolio management or data aggregation.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Rigel’s stock jumps on start of Phase 2 trial for investigational COVID-19 treatment
The P/E ratio of Rigel Pharmaceuticals is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. A $90M net sales run rate based on Q4 sales was mentioned by the CFO, which might be conservative given that Q1’23 is tracking better than expected. Secondly, with net revenues for Rezlidhia expected in 2023, that drug can make a contribution as well.
Just because this past year has been difficult, doesn’t mean that we can’t approach the New Year with a degree of hope. Inflation has shown some signs of moderation, and if that holds, we can look forward to some consequen… The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.
FAQs for Rigel Pharmaceuticals Inc Stock
Putting these things together, it wouldn’t be hard for RIGL to come up with something positive regarding Rezlidhia with Q1’23 earnings. RIGL has announced that it will report Q1’23 earnings on Tuesday, May 2, 2023, and so confirmation of the CEO’s statements regarding Tavalisse might aid a reversal in the stock, which is trading around year-to-date lows. RIGL is a two drug company nowadays, with the recent approval and launch of Rezlidhia, but Tavalisse is still a major story and Q1’23 earnings could see record sales.
- We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes.
- RIGL, +1.86% soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia tr…
- Market cap, also known as market capitalization, is the total market value of a company.
- That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
- 4.88% of the outstanding shares of Rigel Pharmaceuticals have been sold short.
Lastly, delays in reporting results from clinical trials could see the stock trade down even without disappointing data. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company.
Rigel Pharmaceuticals’s Earnings: A Preview
March 7, with Tavalisse net sales of $21.9M for the quarter, up from the quarter prior ($19.2M) and Q4’21 ($17.6M). The sales growth is supported by an increase in the number of bottles shipped to clinics, for example 2,196 bottles were shipped in Q4’22, representing a 23% increase vs Q4’21. Growth that isn’t the result of price increases is a big positive for Tavalisse in the ITP indication. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases.
Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. These returns cover a period from January 1, 1988 through March 6, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research. CompareRIGL’s historical performanceagainst its industry peers and the overall market. Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion. Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch contin…
Articles present my opinion on stocks, but don’t constitute investment advice. RIGL has to make payments to Eli Lilly as part of the RIPK1 inhibitor agreement. RIGL’s agreement with LLY sees the company responsible for 20% of R552 development costs in the US, Europe and Japan up to a specified cap. LLY is expected to initiate a 100 patient, phase 2a trial in rheumatoid arthritis in H1’23 and so RIGL being billed for 20% of those costs should be on the cards.
Style is calculated by combining value and growth scores, which are first individually calculated. Rigel decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia following the FDA’s review. Early clinical data support olutasidenib’s potential as a treatment for AML and MDS, in both the relapsed/refractory and newly diagnosed settings Olutasidenib showed durable remission in treatment-naï… The FDA approves Rigel’s Rezlidhia for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Rigel Pharmaceuticals Inc. said Tuesday afternoon that the drug that has been the company’s main focus has been approved by the Food and Drug Administration. The company last week posted a press release to its website tha…
Rigel Pharmaceuticals Inc RIGL:NASDAQ
So we’re comfortable with our current what is capital position in the business that we’ve discussed today. We — with respect to the path to profitability, we really do as a company, it is a priority for our business to achieve cash flow breakeven… We are reducing our operating expense from about $176 million in 2022, the numbers we just reported, down to what we expect to be about $160 million this year. I would note that over $10 million of the operating expenses I just described are non-cash, they are stock comp and depreciation.
These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share . It can also be calculated by dividing the company’s Market Cap by the Net Profit.
Real-time analyst ratings, insider transactions, earnings data, and more. Rigel Pharmaceuticals’ stock was trading at $1.50 at the beginning of the year. Since then, RIGL shares have decreased by 25.3% and is now trading at $1.12.
These are established companies that reliably pay dividends. / Sales ,37x Nbr of Employees 155 Free-Float 98,3% More FinancialsCompanyRigel Pharmaceuticals, Inc. is a biotechnology company. The risks of any long in RIGL are several fold, a few of which I’ll mention here. Firstly, Rezlidhia sales could underwhelm even if there is growth quarter-over-quarter. Secondly, disappointing results in any of RIGL’s clinical trials could see the stock trade down.
https://1investing.in/ Pharmaceuticals’ stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.75%), Connecticut Wealth Management LLC (0.07%) and Allspring Global Investments Holdings LLC (0.05%). Insiders that own company stock include David A Santos, Dean L Schorno and Raul R Rodriguez. 6 employees have rated Rigel Pharmaceuticals Chief Executive Officer Raul Rodriguez on Glassdoor.com.
High institutional ownership can be a signal of strong market trust in this company. In the past three months, Rigel Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,890.00 in company stock. MarketBeat has tracked 5 news articles for Rigel Pharmaceuticals this week, compared to 2 articles on an average week. 4.88% of the outstanding shares of Rigel Pharmaceuticals have been sold short. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
- Bloomberg Markets European Close Bloomberg Markets European Close.
- A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
- I have no business relationship with any company whose stock is mentioned in this article.
- The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
- Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Basic Materials, Utilities and Industrials sectors propelled shares lower.
The company’s products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This news sentiment score is similar to the average news sentiment of Medical companies. Focus on trading around events such as trial results and NDA/BLA approvals.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.